TDMS Study 05187-09 Pathology Tables
NTP Experiment-Test: 05187-09 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC METHYLEUGENOL Date: 09/15/98
Route: GAVAGE Time: 08:06:17
2 YEAR CHRONIC
Facility: Battelle Columbus Laboratory
Chemical CAS #: 93-15-2
Lock Date: 09/17/96
Cage Range: All
Reasons For Removal: 25022 Accidently Killed 25018 Dosing Accident
25019 Moribund Sacrifice 25020 Natural Death
25021 Terminal Sacrifice
Removal Date Range: All
Treatment Groups: Include All
a Number of animals examined microscopically at site and number of animals with lesion
Page 1
NTP Experiment-Test: 05187-09 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC METHYLEUGENOL Date: 09/15/98
Route: GAVAGE Time: 08:06:17
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS FEMALE 0 MG/KG 37 MG/KG 75 MG/KG 150 300
MG/KG MG/KG
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 60 50 50 50 60
Early Deaths
Natural Death 11 9 13 12 9
Moribund Sacrifice 17 16 14 26 25
Accidently Killed 1
Dosing Accident 1
Survivors
Terminal Sacrifice 22 25 22 11 16
Animals Examined Microscopically 50 50 50 50 50
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Intestine Large, Cecum (50) (50) (50) (50) (50)
Intestine Small, Duodenum (50) (50) (50) (50) (50)
Leiomyosarcoma 1 (2%)
Neuroendocrine Tumor, Malignant, Metastatic,
Stomach, Glandular 1 (2%)
Liver (50) (50) (49) (49) (50)
Cholangiocarcinoma 1 (2%)
Hepatocellular Carcinoma 4 (8%) 6 (12%) 13 (26%)
Hepatocellular Carcinoma, Multiple 2 (4%) 9 (18%)
Hepatocellular Adenoma 1 (2%) 8 (16%) 6 (12%) 10 (20%) 7 (14%)
Hepatocellular Adenoma, Multiple 5 (10%) 23 (47%) 36 (72%)
Hepatocholangiocarcinoma 3 (6%) 7 (14%)
Hepatocholangiocarcinoma, Multiple 2 (4%)
Hepatocholangioma 8 (16%)
Neuroendocrine Tumor, Malignant, Metastatic,
Stomach, Glandular 3 (6%) 10 (20%)
Osteosarcoma, Metastatic, Uncertain Primary
Site 1 (2%)
Mesentery (6) (5) (3) (3) (3)
Oral Mucosa (1) (1)
Squamous Cell Carcinoma 1 (100%)
Pancreas (50) (50) (50) (49) (50)
Salivary Glands (50) (48) (49) (49) (50)
Myoepithelioma 1 (2%)
Stomach, Forestomach (50) (49) (50) (50) (50)
Leiomyosarcoma 1 (2%)
Squamous Cell Carcinoma 1 (2%) 1 (2%)
Squamous Cell Papilloma 1 (2%) 2 (4%)
Stomach, Glandular (50) (50) (50) (48) (49)
Leiomyosarcoma 1 (2%)
Neuroendocrine Tumor, Benign 13 (26%) 9 (19%) 5 (10%)
NTP Experiment-Test: 05187-09 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC METHYLEUGENOL Date: 09/15/98
Route: GAVAGE Time: 08:06:17
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS FEMALE 0 MG/KG 37 MG/KG 75 MG/KG 150 300
MG/KG MG/KG
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM - cont
Neuroendocrine Tumor, Malignant 1 (2%) 12 (24%) 26 (54%) 36 (73%)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (50) (50) (49) (49) (50)
Carcinoma, Metastatic, Uterus 1 (2%)
Schwannoma Benign 1 (2%)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Medulla (50) (50) (50) (49) (50)
Pheochromocytoma Malignant 1 (2%)
Pheochromocytoma Benign 1 (2%) 1 (2%) 2 (4%) 2 (4%) 6 (12%)
Islets, Pancreatic (50) (50) (50) (50) (50)
Adenoma 1 (2%)
Carcinoma 1 (2%)
Neuroendocrine Tumor, Malignant, Metastatic,
Stomach, Glandular 1 (2%)
Pituitary Gland (50) (50) (50) (50) (49)
Pars Distalis, Adenoma 22 (44%) 20 (40%) 21 (42%) 22 (44%) 19 (39%)
Pars Intermedia, Adenoma 1 (2%)
Thyroid Gland (50) (49) (49) (50) (48)
C-Cell, Adenoma 2 (4%) 4 (8%) 2 (4%) 2 (4%)
C-Cell, Carcinoma 1 (2%) 2 (4%) 2 (4%) 2 (4%)
Follicular Cell, Adenoma 1 (2%) 1 (2%) 1 (2%) 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Clitoral Gland (48) (46) (49) (46) (48)
Adenoma 4 (8%) 6 (13%) 4 (8%) 3 (7%) 2 (4%)
Carcinoma 1 (2%) 1 (2%)
Bilateral, Adenoma 1 (2%) 2 (4%) 2 (4%) 2 (4%)
Ovary (50) (50) (49) (49) (50)
Carcinoma, Metastatic, Uterus 1 (2%)
Granulosa Cell Tumor Malignant 2 (4%)
Uterus (50) (50) (49) (50) (50)
Carcinoma 1 (2%)
Hemangioma 1 (2%)
Hemangiosarcoma 1 (2%)
NTP Experiment-Test: 05187-09 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC METHYLEUGENOL Date: 09/15/98
Route: GAVAGE Time: 08:06:17
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS FEMALE 0 MG/KG 37 MG/KG 75 MG/KG 150 300
MG/KG MG/KG
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM - cont
Polyp Stromal 4 (8%) 2 (4%) 3 (6%) 6 (12%) 10 (20%)
Sarcoma Stromal 1 (2%)
Vagina (2) (2)
Fibrosarcoma 1 (50%)
Leiomyosarcoma 1 (50%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (50) (50) (49) (50) (50)
Lymph Node (2) (5) (1) (10) (6)
Mediastinal, Carcinoma, Metastatic, Uterus 1 (20%)
Mediastinal, Neuroendocrine Tumor, Malignant,
Metastatic, Stomach, Glandular 1 (17%)
Pancreatic, Neuroendocrine Tumor, Malignant,
Metastatic, Stomach, Glandular 1 (10%)
Renal, Neuroendocrine Tumor, Malignant,
Metastatic, Stomach, Glandular 1 (17%)
Lymph Node, Mandibular (49) (48) (49) (49) (48)
Lymph Node, Mesenteric (50) (49) (49) (49) (50)
Spleen (50) (50) (50) (49) (50)
Leiomyosarcoma 1 (2%) 1 (2%)
Osteosarcoma, Metastatic, Uncertain Primary
Site 1 (2%)
Thymus (49) (48) (46) (46) (49)
Thymoma Benign 1 (2%)
Thymoma Malignant 1 (2%)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Mammary Gland (50) (50) (50) (50) (50)
Adenoma 1 (2%) 1 (2%)
Carcinoma 2 (4%) 3 (6%) 1 (2%) 4 (8%)
Carcinoma, Multiple 1 (2%)
Fibroadenoma 21 (42%) 23 (46%) 22 (44%) 22 (44%) 16 (32%)
Fibroadenoma, Multiple 15 (30%) 13 (26%) 12 (24%) 9 (18%) 14 (28%)
Skin (50) (50) (50) (50) (50)
Basal Cell Adenoma 1 (2%)
Basal Cell Carcinoma 1 (2%)
Fibrosarcoma 1 (2%)
Trichoepithelioma 1 (2%)
Pinna, Basal Cell Adenoma 1 (2%)
Pinna, Melanoma Malignant 1 (2%)
Subcutaneous Tissue, Fibroma 1 (2%) 2 (4%) 2 (4%) 1 (2%)
Subcutaneous Tissue, Fibrosarcoma 2 (4%)
Subcutaneous Tissue, Lipoma 1 (2%)
NTP Experiment-Test: 05187-09 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC METHYLEUGENOL Date: 09/15/98
Route: GAVAGE Time: 08:06:17
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS FEMALE 0 MG/KG 37 MG/KG 75 MG/KG 150 300
MG/KG MG/KG
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM - cont
Subcutaneous Tissue, Sarcoma NOS 1 (2%)
Subcutaneous Tissue, Schwannoma Malignant 1 (2%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Bone (50) (50) (50) (50) (50)
Chordoma 1 (2%)
Skeletal Muscle (1) (1) (1)
Carcinoma, Metastatic, Uterus 1 (100%)
Rhabdomyosarcoma 1 (100%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (50) (50) (50) (50) (50)
Oligodendroglioma Benign 1 (2%)
Oligodendroglioma Malignant 1 (2%)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (50) (50) (49) (49) (50)
Alveolar/Bronchiolar Adenoma 1 (2%) 1 (2%)
Alveolar/Bronchiolar Carcinoma 1 (2%)
Carcinoma, Metastatic, Uterus 1 (2%)
Carcinoma, Metastatic, Zymbal's Gland 1 (2%)
Chordoma, Metastatic, Bone 1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver 1 (2%) 4 (8%) 4 (8%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%)
Neuroendocrine Tumor, Malignant, Metastatic,
Stomach, Glandular 4 (8%)
Squamous Cell Carcinoma, Metastatic, Oral
Mucosa 1 (2%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Zymbal's Gland (1) (3)
Carcinoma 3 (100%)
____________________________________________________________________________________________________________________________________
NTP Experiment-Test: 05187-09 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC METHYLEUGENOL Date: 09/15/98
Route: GAVAGE Time: 08:06:17
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS FEMALE 0 MG/KG 37 MG/KG 75 MG/KG 150 300
MG/KG MG/KG
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (50) (50) (50) (49) (50)
Transitional Epithelium, Carcinoma 1 (2%)
Urinary Bladder (50) (50) (49) (50) (50)
Carcinoma, Metastatic, Uterus 1 (2%)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(50) *(50) *(50) *(50) *(50)
Leukemia Mononuclear 17 (34%) 20 (40%) 19 (38%) 28 (56%) 17 (34%)
Mesothelioma Malignant 1 (2%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 6
NTP Experiment-Test: 05187-09 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC METHYLEUGENOL Date: 09/15/98
Route: GAVAGE Time: 08:06:17
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS FEMALE 0 MG/KG 37 MG/KG 75 MG/KG 150 300
MG/KG MG/KG
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 47 49 48 47 47
Total Primary Neoplasms 100 121 141 187 232
Total Animals with Benign Neoplasms 43 44 43 43 46
Total Benign Neoplasms 73 86 85 106 127
Total Animals with Malignant Neoplasms 22 28 26 34 39
Total Malignant Neoplasms 27 34 31 46 64
Total Animals with Metastatic Neoplasms 1 3 8 16
Total Metastatic Neoplasm 6 4 9 24
Total Animals with Malignant Neoplasms 1
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant 1 25 35 41
Total Uncertain Neoplasms 1 25 35 41
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
NTP Experiment-Test: 05187-09 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC METHYLEUGENOL Date: 09/15/98
Route: GAVAGE Time: 08:06:17
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS MALE 0 MG/KG 37 MG/KG 75 MG/KG 150 300
MG/KG MG/KG
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 60 50 50 50 60
Early Deaths
Natural Death 15 15 17 29 26
Moribund Sacrifice 15 18 15 20 23
Dosing Accident 1 3 1 1
Survivors
Terminal Sacrifice 20 16 15
Animals Examined Microscopically 50 50 50 50 50
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Intestine Large, Cecum (50) (50) (50) (50) (49)
Intestine Small, Jejunum (50) (50) (50) (50) (50)
Polyp Adenomatous 1 (2%)
Liver (50) (50) (50) (50) (50)
Carcinoma, Metastatic, Pancreas 1 (2%)
Cholangioma 2 (4%)
Fibrous Histiocytoma, Metastatic, Skin 1 (2%)
Hepatocellular Carcinoma 2 (4%) 3 (6%) 13 (26%) 14 (28%) 13 (26%)
Hepatocellular Carcinoma, Multiple 1 (2%) 11 (22%) 23 (46%)
Hepatocellular Adenoma 5 (10%) 7 (14%) 9 (18%) 14 (28%) 8 (16%)
Hepatocellular Adenoma, Multiple 5 (10%) 14 (28%) 24 (48%) 24 (48%)
Hepatocholangiocarcinoma 1 (2%) 1 (2%) 6 (12%)
Hepatocholangiocarcinoma, Multiple 1 (2%)
Hepatocholangioma 1 (2%) 3 (6%)
Hepatocholangioma, Multiple 3 (6%)
Ito Cell Tumor Benign 1 (2%)
Interstitial Cell, Carcinoma, Metastatic,
Testes 1 (2%)
Mesentery (5) (6) (1) (1)
Hepatocellular Carcinoma, Metastatic, Liver 1 (100%)
Leiomyosarcoma 1 (100%)
Oral Mucosa (1)
Pharyngeal, Squamous Cell Papilloma 1 (100%)
Pancreas (50) (50) (50) (50) (49)
Adenoma 1 (2%) 1 (2%)
Carcinoma 1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver 1 (2%) 1 (2%)
Leiomyosarcoma, Metastatic, Mesentery 1 (2%)
Salivary Glands (50) (50) (50) (48) (48)
Schwannoma Malignant 1 (2%)
Stomach, Forestomach (50) (50) (50) (50) (49)
Squamous Cell Carcinoma 1 (2%)
NTP Experiment-Test: 05187-09 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC METHYLEUGENOL Date: 09/15/98
Route: GAVAGE Time: 08:06:17
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS MALE 0 MG/KG 37 MG/KG 75 MG/KG 150 300
MG/KG MG/KG
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM - cont
Squamous Cell Papilloma 1 (2%)
Stomach, Glandular (50) (50) (50) (50) (49)
Neuroendocrine Tumor, Benign 3 (6%) 2 (4%)
Neuroendocrine Tumor, Malignant 4 (8%) 2 (4%)
Tongue (2) (1)
Squamous Cell Papilloma 2 (100%) 1 (100%)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (50) (50) (50) (50) (49)
Endocardium, Schwannoma Malignant 1 (2%)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (50) (50) (50) (50) (50)
Adenoma 1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver 1 (2%)
Adrenal Medulla (50) (50) (50) (50) (50)
Pheochromocytoma Malignant 1 (2%) 1 (2%) 1 (2%)
Pheochromocytoma Benign 18 (36%) 12 (24%) 8 (16%) 8 (16%) 9 (18%)
Bilateral, Pheochromocytoma Benign 6 (12%) 5 (10%) 3 (6%) 2 (4%)
Islets, Pancreatic (50) (50) (50) (50) (49)
Adenoma 3 (6%) 1 (2%)
Parathyroid Gland (48) (49) (48) (45) (46)
Adenoma 1 (2%) 1 (2%)
Pituitary Gland (50) (50) (50) (50) (50)
Oligodendroglioma Malignant, Metastatic,
Brain 1 (2%)
Pars Distalis, Adenoma 7 (14%) 8 (16%) 8 (16%) 2 (4%) 3 (6%)
Thyroid Gland (50) (50) (50) (48) (48)
C-Cell, Adenoma 6 (12%) 4 (8%) 2 (4%) 3 (6%) 1 (2%)
Follicular Cell, Adenoma 2 (4%) 1 (2%) 1 (2%) 1 (2%) 3 (6%)
Follicular Cell, Carcinoma 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
Peritoneum (1) (1) (2) (6) (2)
Squamous Cell Carcinoma, Metastatic, Ureter 1 (50%)
____________________________________________________________________________________________________________________________________
NTP Experiment-Test: 05187-09 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC METHYLEUGENOL Date: 09/15/98
Route: GAVAGE Time: 08:06:17
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS MALE 0 MG/KG 37 MG/KG 75 MG/KG 150 300
MG/KG MG/KG
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Epididymis (50) (49) (49) (50) (50)
Squamous Cell Carcinoma, Metastatic, Ureter 1 (2%)
Preputial Gland (50) (50) (49) (50) (50)
Adenoma 8 (16%) 12 (24%) 3 (6%) 7 (14%) 4 (8%)
Carcinoma 5 (10%) 1 (2%) 2 (4%)
Bilateral, Adenoma 1 (2%) 4 (8%) 1 (2%) 2 (4%)
Prostate (50) (50) (49) (49) (49)
Carcinoma 1 (2%)
Leiomyosarcoma, Metastatic, Mesentery 1 (2%)
Seminal Vesicle (50) (50) (50) (50) (50)
Leiomyosarcoma, Metastatic, Mesentery 1 (2%)
Squamous Cell Carcinoma, Metastatic, Ureter 1 (2%)
Testes (50) (49) (49) (50) (50)
Squamous Cell Carcinoma, Metastatic, Ureter 1 (2%)
Bilateral, Interstitial Cell, Adenoma 45 (90%) 46 (94%) 48 (98%) 46 (92%) 41 (82%)
Interstitial Cell, Adenoma 1 (2%) 2 (4%) 4 (8%) 2 (4%)
Interstitial Cell, Carcinoma 1 (2%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (50) (50) (50) (50) (50)
Fibrous Histiocytoma, Metastatic, Skin 1 (2%)
Lymph Node (8) (4) (4) (4) (3)
Lumbar, Carcinoma, Metastatic, Preputial
Gland 1 (13%)
Lumbar, Fibrous Histiocytoma, Metastatic,
Skin 1 (25%)
Mediastinal, Carcinoma, Metastatic, Pancreas 1 (33%)
Mediastinal, Fibrous Histiocytoma,
Metastatic, Skin 1 (25%)
Mediastinal, Hepatocellular Carcinoma,
Metastatic, Liver 1 (33%)
Renal, Fibrous Histiocytoma, Metastatic, Skin 1 (25%)
Lymph Node, Mandibular (49) (50) (50) (48) (47)
Fibrous Histiocytoma, Metastatic, Skin 1 (2%)
Lymph Node, Mesenteric (50) (50) (49) (50) (48)
Fibrous Histiocytoma, Metastatic, Skin 1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver 1 (2%)
Spleen (50) (50) (50) (50) (49)
Hemangiosarcoma 1 (2%)
Leiomyosarcoma 1 (2%)
Thymus (46) (45) (43) (42) (43)
Thymoma Benign 1 (2%)
____________________________________________________________________________________________________________________________________
NTP Experiment-Test: 05187-09 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC METHYLEUGENOL Date: 09/15/98
Route: GAVAGE Time: 08:06:17
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS MALE 0 MG/KG 37 MG/KG 75 MG/KG 150 300
MG/KG MG/KG
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Mammary Gland (50) (49) (49) (45) (46)
Adenoma, Multiple 1 (2%)
Carcinoma 1 (2%) 2 (4%)
Fibroadenoma 5 (10%) 5 (10%) 10 (20%) 10 (22%) 6 (13%)
Fibroadenoma, Multiple 5 (10%) 3 (7%)
Skin (50) (50) (50) (50) (50)
Basal Cell Carcinoma 1 (2%)
Keratoacanthoma 3 (6%) 3 (6%) 4 (8%) 5 (10%) 2 (4%)
Squamous Cell Papilloma 1 (2%) 1 (2%)
Pinna, Melanoma Malignant 1 (2%) 1 (2%) 1 (2%)
Subcutaneous Tissue, Fibroma 1 (2%) 8 (16%) 6 (12%) 5 (10%) 4 (8%)
Subcutaneous Tissue, Fibroma, Multiple 1 (2%) 2 (4%)
Subcutaneous Tissue, Fibrosarcoma 2 (4%) 2 (4%)
Subcutaneous Tissue, Fibrosarcoma, Multiple 1 (2%) 1 (2%)
Subcutaneous Tissue, Fibrous Histiocytoma 1 (2%)
Subcutaneous Tissue, Hemangioma, Multiple 1 (2%)
Subcutaneous Tissue, Lipoma 1 (2%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Bone (50) (50) (50) (50) (50)
Osteosarcoma 1 (2%)
Skeletal Muscle (1)
Sarcoma NOS 1 (100%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (50) (50) (50) (50) (50)
Oligodendroglioma Benign 1 (2%)
Oligodendroglioma Malignant 1 (2%) 1 (2%) 1 (2%)
Spinal Cord (1) (1) (1)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (50) (50) (50) (50) (49)
Alveolar/Bronchiolar Adenoma 1 (2%) 1 (2%)
Chordoma, Metastatic, Uncertain Primary Site 1 (2%)
Fibrous Histiocytoma, Metastatic, Skin 1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver 1 (2%) 2 (4%) 10 (20%) 22 (45%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%) 1 (2%)
Pheochromocytoma Malignant, Metastatic,
Adrenal Medulla 1 (2%)
Squamous Cell Carcinoma, Metastatic, Ureter 1 (2%)
NTP Experiment-Test: 05187-09 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC METHYLEUGENOL Date: 09/15/98
Route: GAVAGE Time: 08:06:17
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS MALE 0 MG/KG 37 MG/KG 75 MG/KG 150 300
MG/KG MG/KG
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM - cont
Mediastinum, Osteosarcoma, Metastatic, Bone 1 (2%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Zymbal's Gland (1) (2) (1) (1)
Carcinoma 1 (100%) 2 (100%) 1 (100%) 1 (100%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (50) (50) (50) (50) (50)
Fibrous Histiocytoma, Metastatic, Skin 1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver 1 (2%)
Mesenchymal Tumor Benign 1 (2%)
Bilateral, Renal Tubule, Adenoma 1 (2%)
Renal Tubule, Adenoma 3 (6%) 2 (4%) 5 (10%) 6 (12%) 8 (16%)
Renal Tubule, Carcinoma 1 (2%)
Renal Tubule, Oncocytoma Benign 1 (2%) 1 (2%)
Ureter (1)
Squamous Cell Carcinoma 1 (100%)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(50) *(50) *(50) *(50) *(50)
Leukemia Mononuclear 26 (52%) 27 (54%) 15 (30%) 13 (26%) 1 (2%)
Mesothelioma Malignant 1 (2%) 3 (6%) 5 (10%) 12 (24%) 5 (10%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 12
NTP Experiment-Test: 05187-09 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC METHYLEUGENOL Date: 09/15/98
Route: GAVAGE Time: 08:06:17
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS MALE 0 MG/KG 37 MG/KG 75 MG/KG 150 300
MG/KG MG/KG
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 50 50 48 50 46
Total Primary Neoplasms 159 180 176 212 189
Total Animals with Benign Neoplasms 49 50 48 50 46
Total Benign Neoplasms 117 134 133 147 129
Total Animals with Malignant Neoplasms 33 33 34 39 43
Total Malignant Neoplasms 42 46 43 58 56
Total Animals with Metastatic Neoplasms 3 2 4 11 25
Total Metastatic Neoplasm 3 10 4 14 38
Total Animals with Malignant Neoplasms 1
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant 7 4
Total Uncertain Neoplasms 7 4
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
------------------------------------------------------------
---------- END OF REPORT ----------
------------------------------------------------------------